الفهرس | Only 14 pages are availabe for public view |
Abstract A major complication in the treatment of HA is the development of antibodies that inactivate the procoagulant activity of FVIII, increasing the risk of bleeding, physical disability and mortality. Inhibitors occur mainly in children soon after onset of therapy with FVIII concentrate. The incidence of inhibitors in HA patients varies, mainly dependent on the genotype. The measurement of the FVIII inhibitor is achieved by the employment of the Bethesda assay. This is based on the ability of the patient’s plasma containing the FVIII inhibitor to inactivate FVIII present in normal pooled plasma. This work aimed to evaluate the relationship between inhibitor status of haemophilia patients and their QoL and degree of arthropathy and to compare the orthopaedic status of patients with/without inhibitors. The current study was carried on 40 hemophilic patients. All were subjected to full history, through clinical examination, laboratory investigations, including: CBC, FVIII and FVIII inhibitor measurement, X-ray and Dexa. |